Pregnancy Outcomes Following Use of Escitalopram: A Prospective Comparative Cohort Study

Escitalopram is a serotonin reuptake inhibitor prescribed for depression and anxiety. There is a paucity of information regarding safety in pregnancy. The objective of this study was to determine whether escitalopram is associated with an increased risk for major malformations or other adverse outco...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical pharmacology 2012-05, Vol.52 (5), p.766-770
Main Authors: Klieger-Grossmann, Chagit, Weitzner, Brenda, Panchaud, Alice, Pistelli, Alessandra, Einarson, Thomas, Koren, Gideon, Einarson, Adrienne
Format: Article
Language:English
Subjects:
Abnormalities, Drug-Induced - etiology
Abortion
Abortion, Spontaneous - chemically induced
Abortion, Therapeutic
Analysis of Variance
Antidepressants
Antidepressive Agents, Second-Generation - adverse effects
Birth weight
Birth Weight - drug effects
Case-Control Studies
Chi-Square Distribution
Citalopram - adverse effects
Clinical pharmacology
clinical research
drug information
epidemiology
Female
Humans
Infant, Low Birth Weight
Infant, Newborn
Intensive Care Units, Neonatal
Italy
Live Birth
Maternal Exposure
Miscarriage
Ontario
Patient Admission
Pregnancy
Pregnancy Outcome
Prospective Studies
psychopharmacology
Risk Assessment
Risk Factors
Serotonin Uptake Inhibitors - adverse effects
Stillbirth
Switzerland
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Escitalopram is a serotonin reuptake inhibitor prescribed for depression and anxiety. There is a paucity of information regarding safety in pregnancy. The objective of this study was to determine whether escitalopram is associated with an increased risk for major malformations or other adverse outcomes following use in pregnancy. The authors analyzed pregnancy outcomes in women exposed to escitalopram (n = 212) versus other antidepressants (n = 212) versus nonteratogenic exposures (n = 212) and compared the outcomes. Among the escitalopram exposures were 172 (81%) live births, 32 (15%) spontaneous abortions, 6 (2.8%) therapeutic abortions, 3 stillbirths (1.7%), and 3 major malformations (1.7%). The only significant differences among groups was the rate of low birth weight (
ISSN:0091-2700
1552-4604
DOI:10.1177/0091270011405524